GlassScriptPhysician profile
Janish Kothari
NPI 1689105033
$6,456.13
in general payments reported to CMS, 2019-2025
22 companies · $4,525 in 2025
The $4,525 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $192 · 2023: $478 · 2024: $1,261 · 2025: $4,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324 · Travel and Lodging: $1,931 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.70 |
| Travel and Lodging | $1,931.37 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,502.57 | 2024-2025 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $1,417.90 | 2023-2025 | Triclip, Cardiomems, Mitraclip |
| Medtronic, INC. | $587.73 | 2024-2025 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $440.72 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $395.60 | 2024 | Wegovy |
| Heartflow, INC. | $367.55 | 2024-2025 | |
| Cvrx, INC. | $341.13 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $235.91 | 2023-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.78 | 2022-2025 | Jardiance |
| Amgen INC. | $166.24 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $157.57 | 2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $142.88 | 2025 | Sapien 3 Ultra Resilia |
| United Therapeutics Corporation | $125.00 | 2025 | Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $111.50 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $101.40 | 2023-2025 | Farxiga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.11 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.98 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.90 | 2025 | Entyvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.96 | 2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $16.86 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $14.37 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janish Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.